RGNX250117C5000
- 2.35
- 0.000.00%
Regenxbio Newsroom
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $30
RegenXBio (RGNX) Gets a Buy From RBC Capital
Regenxbio Analyst Ratings
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $36
Analysts Offer Insights on Healthcare Companies: NewAmsterdam Pharma Company (NAMS), Illumina (ILMN) and RegenXBio (RGNX)
Morgan Stanley Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $22
Stifel Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $40
Strategic Partnerships and Promising Pipeline Drive Buy Rating for RegenXBio
BofA Securities Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $22
Bank of America Securities Sticks to Their Buy Rating for RegenXBio (RGNX)
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $30
BofA Securities Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $22
RBC Capital Reiterates Outperform on Regenxbio, Maintains $35 Price Target
Regenxbio Analyst Ratings
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $35
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $36
Buy Rating on RegenXBio Driven by Positive RGX-202 Trial Results and Strong Approval Prospects
Barclays Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $50
REGENXBIO Is Maintained at Buy by Chardan Capital
REGENXBIO Price Target Maintained With a $52.00/Share by Chardan Capital